Altamira Therapeutics Ltd. (CYTOF)
OTC Markets OTCID
Price as at 30 Sept 2026, 17:27 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Altamira Therapeutics Ltd. trades at $0.08. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland, Australia, the United States, and Europe. The company develops and supplies peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues through xPhore platform; and offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens It is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; and AM-125 that is in post phase II clinical trial for the intranasal treatment of vertigo. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its CYTOF data?
Fundamentals for CYTOF come from company filings and exchange data, as listed on OTC Markets OTCID; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 17:27 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for CYTOF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.